I read with great interest the paper by Shafran and Burgunder [1] and the Editorial comment by Day and Gearry [2] about the efficacy of rifaximin in inducing and maintaining remission in patients with Crohn's disease.
As discussed by the authors, the beneficial role of rifaximin in this setting supports the view that the intestinal flora plays a pivotal role in the pathophysiology of Crohn's disease. This concept, however, applies as well to ulcerative colitis [3, 4] .
The possible therapeutic effect of rifaximin in the treatment of ulcerative colitis has received scarce attention so far, but I would like to report our pilot experiences in this area [5] [6] [7] .
In 30 patients with a history of steroid intolerance, experiencing a mild to moderate clinical flare-up of ulcerative colitis while on maintenance treatment with mesalamine 2.4 g daily, rifaximin 400 mg b.i.d. was added for 4 weeks. At the end of the treatment period, clinical remission was obtained in 76.6% of cases [6] .
More recently, a selected group of six patients with leftsided ulcerative colitis, intolerant to mesalamine and unwilling to undertake immunosuppressive therapy, was allocated to a maintenance treatment with a combination of Saccharomyces boulardii 500 mg in the morning plus rifaximin 400 mg in the evening. At 3 months, all subjects were still in remission [7] .
Four patients who continued the above treatment schedule for a further period were still in remission at 6 months (data on file).
Our preliminary data, which obviously need to be confirmed by controlled studies on a larger number of patients, suggest that manipulating the gut microbiota by means of a non-absorbable antibiotic such as rifaximin can have a beneficial effect in the pharmacological treatment of inflammatory bowel disease, including ulcerative colitis.
